An enduring grand round presentation focusing on new therapeutic options for managing recurrent advanced ovarian cancer.

This educational initiative will:

• Review the the role of angiogenesis inhibitors in the management of recurrent advanced ovarian cancer.
• Discuss the role of homologous recombination deficiency in the development of recurrent advanced ovarian cancer.
• Describe the mechanism of action, efficacy, and safety of PARP inhibitors approved to treat advanced ovarian cancer.
• Outline the management of patients with recurrent advanced ovarian cancer by incorporating angiogenesis inhibitors or PARP inhibitors into a management program.
• Outline strategies for engaging patients about PARP inhibitor use to promote adherence to therapy.

This activity is intended for oncologists, gynecologists, and other clinicians including nurse practitioners (NPs), physician assistants (PAs), and nurses who encounter patients with ovarian cancer. There are no prerequisites for this activity.

https://www.cmecorner.com/programs.asp?audience=&ProductID=2326&partner=JHU

The release date: Thursday, May 23, 2019
The expiration date: May 23, 2020

1. Discuss the role of angiogenesis inhibitors in the management of recurrent advanced ovarian cancer.
2. Discuss the role of homologous recombination (HR) deficiency in the development of recurrent advanced ovarian cancer.
3. Describe the mechanism of action, efficacy, and safety of PARP inhibitors approved to treat advanced ovarian cancer.
4. Outline the management of patients with recurrent advanced ovarian cancer by incorporating angiogenesis inhibitors or PARP inhibitors into a management program.
5. Outline strategies for engaging patients about PARP inhibitor use to promote adherence to therapy.

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

No faculty are available for this activity at this time.